CCO Expert Recap

Focus on Investigational HCV Agents

Source: 2008 Annual Meeting of the European Association for the Study of the Liver*

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Focus on Investigational HCV Agents

Faculty:

Nezam H. Afdhal, MD, FRCPI headshot
  • Nezam H. Afdhal, MD, FRCPI

CME CREDIT INFORMATION

Release Date: 08/20/08

Expiration Date: 08/19/09


Physicians: maximum of 1.0 AMA PRA Category 1 Credit(s)™

Status: Please log in to view status


Nezam H. Afdhal, MD, FRCPI, discusses the latest data on novel agents for the treatment of chronic hepatitis C

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Summarize data from the PROVE studies of telaprevir and peginterferon/ribavirin for the treatment of genotype 1 hepatitis C virus–infected patients
  • Discuss the safety and efficacy of boceprevir for the treatment of treatment-naive and nonresponder patients with genotype 1 chronic hepatitis C
  • Recount data on novel polymerase inhibitors for the treatment of chronic hepatitis C
  • Describe the importance of ribavirin in treating chronic hepatitis C and the role of ribavirin analogues
  • Discuss anti–hepatitis C virus agents with novel mechanisms of action

Slideset

Focus on Investigational HCV Agents


Download and review key data selected by Nezam H. Afdhal, MD, FRCPI, on investigational HCV agents that was presented at the 2008 EASL meeting in Milan. Use the slides in your own presentations!


Format: Microsoft PowerPoint (.ppt) | File size: 717 KB

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Educational grant provided by:

Educational grants support only the CME-certified components of this program.